Inderjit Mehmi

Medical Oncologist•The Angeles Clinic and Research Institute•Melanoma•Merkel Cell Cancer•Clinical Trial Concierge

[Omid Hamid MD @OmidHamidMD]

@angelesclinic we believe in education and discovery. @mi_onc discusses updates in Melanoma Research Foundation hashtag
#CureOM in #OcularMelanoma from @ASCO
https://t.co/nK0RjUSIOg

[Omid Hamid MD @OmidHamidMD]

@angelesclinic we believe in #education and #discovery. Dr. Inderjit Mehmi @Mi_onc discusses updates in #Melanoma @CureMelanoma #CureOM in Ocular Melanoma from @ASCO
https://t.co/YwM5R0mlVW

[Inderjit Mehmi @Mi_onc]

Need help!
@canyon_bikes
Headset tool GP7203-01, need to borrow/buy
@westlakevillage @CityofTO #roadbike

[Omid Hamid MD @OmidHamidMD]

This is off the shelf bespoke T cell therapy

[NEJM @NEJM]

Presented at #ASCO24:

Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those who received only adjuvant therapy. Full NADINA trial results: https://t.co/ZxWxo2qgNy

[Inderjit Mehmi @Mi_onc]

The Boss

[Omid Hamid MD @OmidHamidMD]

Spotlight on @angelesclinic @ASCO #ASCO24 only US site to contribute to NADINA Plenary
#neoadjuvant therapy that will change the face of #immunotherapy for all cancers @NKI_nl @ProfCUBlankNKI @ProfGLongMIA @MelanomaAus @MarkFariesMD @Mi_onc

https://t.co/360Zap1N2v

[Omid Hamid MD @OmidHamidMD]

Reposting as #MelanomaAwarenessMonth begins....
https://t.co/hRXMlIAECf

[Omid Hamid MD @OmidHamidMD]

Melanoma Symposium @angelesclinic @AIMatMelanoma March 11th onsite and virtual
Patients, Cargivers, physicians, all welcome
https://t.co/hRXMlIA6MH

[Inderjit Mehmi @Mi_onc]

@OmidHamidMD You should use that pic of @KrisWentzelMD and me in black scrubs to make your point?

[Inderjit Mehmi @Mi_onc]

@FDimitriouMD @MelanomaReAlli @MDAndersonNews @JenWargoMD Congrats!
Well deserved

[Omid Hamid MD @OmidHamidMD]

Melanoma Education Symposium (Free ) Virtual and In-Person @angelesclinic with @AIMatMelanoma support. Wonderful talks , informative

https://t.co/IVJzXbs8YC

@DrSapnaPatel @Mi_onc @jtmoyers @AnthonyNguyenMD @MarkFariesMD @MDAndersonNews @CSCancerCenter @CedarsSinaiMed @MGHMedicine @CUCancerCenter @CUAnschutz

[Justin Moyers @jtmoyers]

Talking about updates in the world of melanoma at MOASC summit in NB tomorrow! @MOASC_Office

I’ll be talking about exciting updates in world of melanoma treatment and novel therapeutics in research @angelesclinic with @Mi_onc @OmidHamidMD @CSCancerCenter !

[Inderjit Mehmi @Mi_onc]

What an opportunity to be part of this project!
#clinicaltrials @angelesclinic
@CSCancerCenter

[Richard Schilsky @rschilsky]

Just published by @ASCO #TAPUR. Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology https://t.co/P4BvB7XB6J

[Inderjit Mehmi @Mi_onc]

#clinicaltrial at @angelesclinic @CSCancerCenter #TAPUR @ASCO
One step at a time

[Vivek Subbiah, MD @VivekSubbiah]

Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study | JCO Precision Oncology @ASCO @rschilsky @JCOPO_ASCO @OncoAlert
https://t.co/LZuogm4S6Y

[Inderjit Mehmi @Mi_onc]

@OmidHamidMD @IovanceBio @US_FDA @angelesclinic @CSCancerCenter @jtmoyers Let this be a door way for a new therapeutic options for other solid malignancies.
#clinicaltrials #TIL #melanoma
@angelesclinic @CSCancerCenter
“Hope is the first step” next step is work to that hope!

[Inderjit Mehmi @Mi_onc]

What will you use in 2nd line for melanoma patients, if these data give you pause? Asking for my patients!

[Omid Hamid MD @OmidHamidMD]

Congrats @IovanceBio with @US_FDA approval of TIL therapy! Proud to be part of this revolution @angelesclinic @CSCancerCenter The race is not over but we are closer @Mi_onc @jtmoyers

[Inderjit Mehmi @Mi_onc]

@ad1600 @BhatiaS_MD @HibaMKhanMD @EvanHallMD @ShankaranVeena @csoncol @CureMelanoma @sitcancer @jasonlukemd @MPostow @diwakardavar @OmidHamidMD @DrBetofMDPhD @FunchainMD @DrKellyPaulson @ProfGLongMIA Also looking forward to development of new CTLA-4 targeting mabs looking to push dose without increasing tox.

[Inderjit Mehmi @Mi_onc]

@ad1600 @BhatiaS_MD @HibaMKhanMD @EvanHallMD @ShankaranVeena @csoncol @CureMelanoma @sitcancer @jasonlukemd @MPostow @diwakardavar @OmidHamidMD @DrBetofMDPhD @FunchainMD @DrKellyPaulson @ProfGLongMIA Prefer ipi 3 nivo 1 , also forced to do so, since most cone with high risk disease with brain/liver /high tumor burden